Hong Kong needs new funding model to draw investment from global drug makers: AstraZeneca

Hong Kong can attract more global biotech investments if the city builds up a new healthcare financial model, according to AstraZeneca, a Cambridge-based multinational pharmaceutical giant. While global drug makers have been doubling down on investments in mainland China in recent years, AstraZeneca brought over 60 clinical trials to the city and invested over HK$200 million (US$25.5 million) over